Join Oculis for an in-person and virtual R&D Day to present the company’s portfolio in neuro-ophthalmology and ophthalmology, review clinical progress, and discuss development strategy.

Presentations will provide updates on:

• Licaminlimab’s PREDICT-1 registrational trial inTNFR1-mediated dry eye disease (DED) with topline results anticipated around year-end.
• Privosegtor’s PIONEER clinical program advancement in optic neuropathies and development strategy including acute MS relapse.

A live question and answer session will follow the formal presentations.